Alessandro Villa, DDS
Oral and Maxillofacial Surgery · Miami, FLNPI 1841580453
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,994 of the $14,059 with a category attached, or 99.5%. Merck accounts for 69.1% of it on its own, with 4 other manufacturers making up the rest. Among oral and maxillofacial surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $1278.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10K
- Amgen$2K
- Kowa Pharmaceuticals America, Inc.$2K
- Galt Pharmaceuticals, LLC$300
- Caris MPI, Inc.$65
Across 1 payment — averaging $112,043 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$112K
What the payments were for
- Consulting fees$13,994100%
- Food & beverage$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $9,710 |
| Amgen | 4 | $2,244 |
| Kowa Pharmaceuticals America, Inc. | 1 | $1,740 |
| Galt Pharmaceuticals, LLC | 1 | $300 |
| Caris MPI, Inc. | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,059 in reported general payments places this provider in the 95th percentile of 498 oral and maxillofacial surgery providers in Florida.
See all oral and maxillofacial surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 25 | $2,897 |
| Cevimeline Hcl | 18 | $2,679 |
| Gabapentin | 51 | $2,417 |
| Clobetasol Propionate | 19 | $1,358 |
| Fluocinonide | 18 | $1,073 |
| Dexamethasone | 28 | $613 |
| Nystatin | 34 | $578 |
| Fluconazole | 28 | $365 |
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $245 |
| Chlorhexidine Gluconate | 46 | $194 |
Paid to pharmacies, not to this prescriber.
Other oral and maxillofacial surgery in Miami
- Jose MonteroMiami$42K
- Ramzey TursunMiami$42K
- Robert MarxMiami$17K
- Neel PatelMiami$14K
- Hisham MarwanMiami$10K
- Molie XuMiami$9K
- Kroum DimitrovMiami$7K
- Michael PikosPalm Harbor$3M
- Ramon RuizOrlando$846K
- Curtis SchalitDaytona Beach$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.